October 27, 2021 5:21pm

The question revolves around what is determined to be the “spinner” in these markets

Pre-open indication results: 4 HITs, 1 MISS and 1 PUMPED

My version of the session’s “indications” is about what you need to know; it’s what did happen after the opening, mid-day and to the close

An objective, fact and numbers-based narrative – check the numbers!

The Dow closed -266.19 points (-0.74%); the S&P closed DOWN -23.11 points (-0.51%) while the Nasdaq closed FLAT points (0.00%)

 

Henry’omics:

Indexes were playing “chutes and ladders” … “when playing the game, it’s about how going down a slide helped to later go up a ladder”. This can symbolize how much of equity movement has come from previous mistakes and failures.”

Wednesday, the Dow dived, the S&P 500 turned lower after the Nasdaq rallied 0.00% (+0.12 points) in Wednesday’s trade.

Losses in Alnylam Pharmaceuticals (ALNY -$6.55), Fate Therapeutics (FATE -$4.47) ReNeuron (RENE.L -$2.50), Intellia Therapeutics (NTLA -$2.40), CRISPR Therapeutics (CRSP -$2.28), and Editas Medicine (EDIT -$1.10) and twenty-three (23) other sector equities defined the decline while few like Global Blood Therapeutics (GBT +$2.79), BioLife Solutions (BLFS +$1.23), Ultragenyx Pharmaceuticals (RARE +$1.15) and bluebird bio (BLUE +$1.11), appreciated in “our” universe.

The benchmark 10-year U.S. Treasury yield declined for a fourth straight day, dropping 8 basis points to put it on track for its biggest one-day decline since July 19.

 

Note: Biostage (BSTG) was down -$0.40 with 216 shares traded until the “pimp or pump” was turned-on with 1,676 shares traded – where is the SEC?

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Wednesday opened negative at 13/17, 4 flats and 1 acquired, stayed negative at the mid-day at 13/20, 1 flat and 1 acquired, ending with a negative close of 10/23, 1 flat and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “get out the dice, take some risk on selling more of the oversold and buying some of the underbought. After a six (6) sector stumbles out of seven (7) sessions, the probabilities of some upside are still relative.” …  https://www.regmedinvestors.com/articles/12156

 

Pre-open indication results: 4 Hit: <SELL into Strength: bluebird bio (BLUE +$1.11), Cellectis SA (CLLS -$0.16), Mesoblast (MESO -$0.18); Maintain SELL into Strength: BioLife Solutions (BLFS +$1.23)> and 1 MISS <uniQure NV (QURE +$0.68)> 1 Pimped or was it Pumped: Biostage (BSTG +$0.10)>  

 

Key Metric - volume:

Sector volume was INCREASED with 1 of the 10-upside having higher than the 3-month average volume with INCREASING volume of 7 of 23-downside having higher than the 3-month average volume;

 

There are clear winners and losers

Jumping with share pricing momentum (10 of 10):

  • Global Blood Therapeutics (GBT +$2.79 after Tuesday’s -$0.86 and Monday’s -$0.71),
  • BioLife Solutions (BLFS +$1.23 after Tuesday’s +$1.99 and Monday’s +$2.28),
  • Ultragenyx (RARE +$1.15 after Tuesday’s +$0.81 and Monday’s +$1.47),
  • bluebird bio (BLUE +$1.11 after Tuesday’s -$0.28 and Monday’s +$0.43),
  • uniQure NV (QURE +$0.68 after Tuesday’s -$0.98 and Monday’s +$0.90),
  • AxoGen (AXGN +$0.32 after Tuesday’s +$0.31 and Monday’s -$0.20),
  • Biostage (BSTG +$0.10),
  • Chinook Therapeutics (KDNY +$0.04 after Tuesday’s +$0.03 and Monday’s -$0.21),
  • Bellicum Pharmaceuticals (BLCM +$0.03),
  • Voyager therapeutics (VYGR +$0.02),

Hammered in today’s market (10 of 23):

  • Alnylam Pharmaceuticals (ALNY -$6.55 after Tuesday’s -$1.96 and Monday’s +$1.06),
  • Fate Therapeutics (FATE -$4.47 after Tuesday’s +$1.15 and Monday’s -$0.84),
  • ReNeuron (RENE.L -$2.50 after Tuesday’s +$4.00 and Monday’s +$1.50),
  • Intellia Therapeutics (NTLA -$2.40 after Tuesday’s -$1.55 and Monday’s +$1.97),
  • CRISPR Therapeutics (CRSP -$2.28 after Tuesday’s -$1.64 and Monday’s +$1.14),
  • Editas Medicine (EDIT -$1.10 after Tuesday’s -$0.31 and Monday’s +$0.39),
  • Sage Therapeutics (SAGE -$1.04),
  • Regenxbio (RGNX -$0.76 after Tuesday’s -$0.57 and Monday’s +$0.41),
  • Homology Medicine (FIXX -$0.25),
  • Vericel (VCEL -$0.24),

Closing Flat:

  • 1 – Caladrius Biosciences (CLBS) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed down -1.56% and XBI closed down -1.44%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was up +1 points or +6.26% at 16.98

 

October, the first month of Q3/21:

Wednesday closed negative with 10 advancers, 23 decliners, 1 flat and 1 acquired

Tuesday closed negative with 9 advancers, 24 decliners, 1 flat and 1 acquired

Monday (10/25) closed negative with 15 advancers, 17 decliners, 2 flat and 1 acquired

 

 

The BOTTOM LINE:  What I wrote yesterday, still is relevant … “Don't let earnings week take advantage of you. Be ready to act on up-coming earnings news, good or bad, but don't be too hasty.”

I say take ANY profit if one can … to have “powder” after the “drops” …

We'll be seeing the results these couples of weeks as Alnylam Pharmaceuticals (ALNY) on 10/28 followed by Sage Therapeutics (SAGE) and Ultragenyx Pharmaceuticals (RARE) on 11/2, Fate therapeutics (FATE) on 11/4, Vericel (VCEL on 11/9 and Athersys (ATHX) on 11/15 – so far.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.